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Abstract: Objective: To study the effect of check width size of the stimuli on the amplitude and latency
of the P100 component of visual evoked potentials recorded in patients with retinitis pigmentosa
(RP). Methods: Pattern reversal visual evoked potentials (PVEPs) were recorded in 16 RP patients
and 20 visually normal subjects. Pattern reversal stimuli with five different check widths and 100%
of contrast were projected in the right eye of both patients and control subjects. PVEPs induced by
stimuli with 78%, 16%, and 6% of contrast were also recorded in 10 of the control subjects. Results:
In RP patients, the amplitude of P100 was smaller than controls in all check sized used and the peak
P100 amplitude was obtained with a larger check width than in controls. P100 was also delayed
in RP patients in all check sizes studied. The P100 amplitude- and latency-check size functions
of RP patients were like those found in control subjects with low contrast stimuli of 16% and 6%.
Conclusion: The PVEPs spatial functions of RP patients show quantitative and qualitative changes,
suggesting disease induced alteration in the neural processing of stimulus contrast.
Keywords: pattern reversal visual evoked potentials; P100-spatial functions; retinitis pigmentosa;
visual cortex
1. Introduction
Retinitis pigmentosa (RP) refers to a heterogeneous group of inherited, progressive, retinal disorders
characterized by abnormalities of the photoreceptors and the retinal pigment epithelium that lead to
progressive visual loss [1,2]. RP has a combined incidence of approximately 1/3500. In typical cases,
known as rod-cone RP, the rods are the predominantly affected cells, and the main symptoms are night
blindness and bilateral symmetric loss of peripheral visual field. Although there is usually relative
preservation of macular vision, with progression, cone photoreceptor cells are also affected, and day
vision and visual acuity are compromised. The variant that involves simultaneous cone photoreceptor
degeneration, referred as cone-rod RP, shows a more central loss of the visual field and greater early
changes in cone dominated central retina. RP is associated with an expanding number of newly
identified gene mutations that alter the visual transduction cascade and photoreceptor transcription and
structure [3–5]. At present, there is no therapy for stopping the progression of the disease. However,
vision rescue strategies are expected in the development of protective neurotrophic agents, gene therapy,
retinal transplantation, and bionic implants of stem/engineer cells [6–9].
There are several ways of monitoring the visual loss in patients with RP. Objective electrophysiological
tools, such as the visual evoked potentials (VEP), have been of major importance for this purpose [10].
The VEP, resulting from signal averaging of the electroencephalographic activity recorded at the occipital
pole, provide information regarding the functional integrity of the visual system, from the retina to
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the visual cortex [11]. Pattern reversal visual evoked potentials (PVEPs), which use as stimuli black
and white checks that change phase abruptly, is the preferred method since the results are less variable
in waveform and timing than those elicited by other stimuli [12]. PVEPs generated in the occipital
cortex represent the primary cortical visual processing elicited by stimulation of the ganglion cells in the
macula. PVEPs recordings consist of N75, P100, and N135 peaks, designating peaks as negative and
positive followed by the typical peak latency in ms. The P100 peak is the most robust PVEPs component
and valuable for clinical diagnosis since it shows relatively little variation between normal subjects,
minimal within-subject interocular difference, and minimal variation with repeated measurements over
time [11,12].
In RP patients, recording of PVEPs is particularly useful to objectively evaluate the residual visual
capacity since the activity of the visual cortex can be detected in those patients with no response
to other electrophysiological techniques, such as the electroretinogram [13]. In previous studies,
PVEPs recordings in RP using a single check width [13,14] showed an attenuation of amplitude of
the P100 and, in some cases, delayed latency, but the effects of different check widths P100 amplitude
and latency-spatial functions have not yet been described in these patients. Since the amplitude and
latency of P100 are sensitive to the check size of the stimuli [15,16], the aim of the present study was to
investigate in RP patients the effects of different check widths in both the amplitude and latency of
P100. Using different check widths will also allow us to obtain P100 amplitude- and latency-check size
functions of RP patients.
2. Materials and Methods
A total of 16 patients with RP (age range 23–57 years, 4 males) participated in the study. The clinical
characteristics of the patients are listed in Table 1. The inclusion criteria were the ophthalmic appearance
of typical RP, with narrow retinal arteries, bone spicule pigmentation, or diffuse retinal pigment
epithelium degeneration, and an abnormal or non-recordable electroretinogram. Patients were excluded
if they had ophthalmic disorders (e.g., cataract) or neuroophthalmic symptoms (e.g., nystagmus), or if
they were under any kind of topical or systemic medication. All RP patients included in the study
had night blindness, constriction of the visual field and, except for two patients, reduction of visual
acuity. The normal controls were 20 subjects (age range 19–60 years, 8 males). They were healthy, on no
medication, had no history of ophthalmic or neurological disorders, and their visual acuity was 1.0 or
better. The study adhered to the tenets of the Declaration of Helsinki, and it was approved by the Ethical
Committee of the University of Granada. An informed written consent was obtained from all subjects.
The recording of PVEPs followed the standard of the International Society for Clinical
Electrophysiology of Vision [11]. Subjects were positioned 114.5 cm from the stimulus display.
The PVEPs were recorded monocularly (right eye) in a dark room. The active electrode was positioned
at the Oz (International 10–20 system), the reference electrode at Fz and ground electrode at Cz. Electrode
impedance was below 1 kΩ. We used the square-wave, checkerboard, pattern reversal stimulus (1 Hz)
presented by a television monitor (EEVOKE system, from Advance Neurotechnology software BV,
ANT systems. Enschede, The Netherlands). The overall stimulus field was 24 cm × 32 cm, subtending
a visual angle of 11.8◦ × 15.6◦. We measured the PVEPs using five different sizes of black and white
checks: 60′, 30′, 15′, 7.5′, and 3.75′ (minutes of arc) of check width, corresponding to spatial dominant
frequencies of 0.71, 1.41, 2.83, 5.66, and 11.31 cycles per degree (cpd), respectively. The Michelson
contrast({[Lmax− Lmin]/[Lmax + Lmin]}× 100) was 100%, where L = luminance, max = maximum and
min = minimum, and the mean luminance was 50 Cd/m2. To study the effects of stimulus contrast on
PVEPs, in 10 of the control subjects, stimuli of 78%, 16%, and 6% of contrast was also used. The PVEPs
elicited were fed into a signal-averaging computer system (Advance Source Analysis, ANT systems.
Enschede, The Netherlands). The signals were amplified and passed through a band-pass filter at
between 1 Hz and 100 Hz. Experimental sessions consisted of the presentation of 200 stimuli, and the
analysis time was 500 ms.A mean of 195 stimuli were averaged for analysis. The results were analyzed
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by a one-way ANOVA and Bonferroni tests with STATA 10.1 software.Data were presented as the
mean ±SEM. p < 0.05 was considered statistically significant.
Table 1. Clinical characteristics of the patients.
Patient Sex Age Visual Inheritance
(Years) Acuity Pattern
Group RP1
1 Female 54 0.40 S
2 Female 51 0.67 AR
3 Male 35 1.00 AR
4 Male 25 0.67 AD
5 Female 23 1.00 AD
6 Female 50 0.40 S
7 Female 35 0.40 AD
8 Male 30 0.40 AD
Group RP2
9 Male 52 0.40 S
10 Female 40 0.40 S
11 Female 48 0.20 AD
12 Female 29 0.10 AR
13 Female 52 0.05 AR
14 Female 57 0.40 AR
15 Female 38 0.67 S
16 Female 48 0.29 S
AD, autosomal dominant; AR, autosomal recessive; S, simplex.
3. Results
Figure 1 shows individual PVEPs recording obtained in 100% of contrast and with the check
width where controls and RP patients had the largest amplitude (15′ and 60′, respectively). The mean
amplitude of P100 (measured from N75 peak) was 10.8 µV for controls and 2.71 µV for RP patients.
In contrast to controls, differences in the amplitude of P100 in RP patients (Figure 1b) clearly show the
existence of two groups of patients, one of each with larger amplitude of the PVEPs.
The first group called RP1 was composed of patients 1–8, and the second called R2 was composed
of patients 9–16 (Table 1). RP1 group had better visual acuity and larger amplitude of PVEPs than the
second group of patients (Table 2). Thus, RP1 group shows a mean visual acuity of 0.62 in decimal
scale, peak P100 amplitude between 4.12 µV and 9.7 µV, and mean of age 37.9 ± 12.22 years. RP2 group
had a mean visual acuity of 0.31, peak P100 amplitude between 1.25 µV and 4 µV, and mean of age
45.5 ± 9.17 years. Differences in visual acuity and P100 amplitude were significant between both
groups (p < 0.01), but differences in age were not. To have a control group equivalent in age with
RP patients, healthy subjects were divided in two groups of 10 individuals (Table 2), C1 (mean of
age 19.3 ± 0.48 years, 4 males) and C2 (mean of age 37.5 ± 10.74 years, 4 males). In RP1, RP2, and C2
groups the contrast stimuli used was 100%. In C1 group, stimuli were presented with contrasts of
100%, 78%, 16%, and 6%. Table 2 shows the P100 amplitude and latency obtained with the different
contrasts and in the four experimental groups.
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Table 2. Amplitude and latency values (mean ± SEM) of P100 in healthy controls (C1, C2) and RP patients (R1, R2).
CheckWidth Group
(cpd) C1 C2 RP1 RP2
100% 78% 16% 6% 100% 100% 100%
Amplitude (µV)
0.71 9.18 ± 2.05 7.81 ± 2.89 3.70 ± 0.97 a 2.22 ± 0.96 a 9.60 ± 2.18 5.70 ± 1.93 d 2.54 ± 0.84 c,f
1.41 9.41 ± 2.53 8.97 ± 3.27 3.97 ± 1.84 a 3.15 ± 1.68 a 10.06 ± 1.70 5.08 ± 1.15 c 1.95 ± 0.89 c,e
2.83 10.59 ± 2.66 9.39 ± 2.79 4.29 ± 1.36 a 2.80 ± 1.14 a 11.54 ± 1.37 4.35 ± 0.90 c 1.46 ± 0.59 c,e
5.66 6.99 ± 1.81 7.33 ± 2.72 2.71 ± 1.31 a 1.69 ± 0.60 a 6.17 ± 1.97 2.64 ± 0.45 d
11.31 3.29 ± 1.85 2.56 ± 1.09 2.99 ± 0.81 1.47 ± 0.57
Latency (ms)
0.71 104.27 ± 4.40 102.22 ± 4.05 107.79 ± 6.45 116.31 ± 7.57 a 102.61 ± 4.91 102.44 ± 4.60 108.71 ± 12.69
1.41 104.66 ± 3.52 103.58 ± 5.17 110.39 ± 4.43 116.95 ± 5.56 b 102.12 ± 2.62 107.93 ± 5.29 120.57 ± 15.68 d
2.83 108.45 ± 3.46 108.37 ± 4.61 116.93 ± 7.04 129.77 ± 9.40 a 107.19 ± 4.19 115.36 ± 9.50 126.70 ± 17.38 d
5.66 117.13 ± 4.14 118.41 ± 5.65 131.49 ± 6.96 b 143.00 ± 1.47 a 116.66 ± 5.37 122.15 ± 10.82
11.31 128.22 ± 5.11 132.89 ± 9.33 132.86 ± 9.37 136.53 ± 10.97
a p < 0.001, b p < 0.05 compared with 100% of contrast of C1; c p < 0.001, d p < 0.05 compared with C2; e p < 0.001, f p < 0.01 compared with RP1; cpd, cycles per degree.
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Fig re 1. PVEPs obtained in (a) control subjects and (b) RP patients with the check width that produced
the largest amplitude of the P100; 15′ and 60′, respectively. (c,d) averaged PVEPs of controls and
patients, respectively. N75, P100 and N135 peak components are indicated.
Amplitude and latency of the averaged PVEPs obtained in control C1 group subjects with stimuli
of 78% and 100% of contrast were similar (Figure 2a,b). However, stimuli of 16% and 6% reduced the
amplitude and delayed the latency of PVEPs components (Figure 2c,d). Both groups of RP patients
(Figure 2f,g) showed smaller amplitudes and longer latencies of PVEPs when compared with their
control C2 group (Figure 2e).The differences in P100 amplitude between the RP1 and RP2 groups were
significant in all check widths. In contrast, no significant differences were observed in latency.
Figure 3 shows a box plot where the differences in the amplitude of the P100 of the different
groups investigated can be better appreciated. The figure shows the data obtained with the check
widths where the largest P100 amplitude in the different experimental groups was obtained (15′ for C1
and C2, and 60′ for RP1 and RP2).
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Spatial functions of the P100 VEP component obtained in the control C1 group are shown in
Figure 4 and that of C2, RP1, and RP2 groups are shown in Figure 5. Control C1 group shows similar
P100 amplitude-check width functions for stimuli of 100% and 78% of contrast (Figure 4a). However,
smaller contrasts (16% and 6%) produced a significant (p < 0.001) over-all reduction of the P100
amplitude. With these two low contrasts, PVEPs were non recordable at the smallest check width
tested of 3.75′. The largest amplitude of P100 was obtained with the check size of 15′ for stimuli of
100%, 78%, and 16% of contrast and with 30′ for the contrast of 6%. On the other hand, the P100
latency-check width functions of the C1 control group showed longer P100 latencies with stimuli of
16% and 6% in all check sizes tested (Figure 4b).
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Compared with age equivalent controls (C2 group), the P100 amplitude-check width function
obtained in RP patients showed an overall reduction of the amplitude (Figure 5a). In RP1 group,
the decrease in P100 amplitude was significant at the check sizes 7.5′ and 60′ (p < 0.05) and at 15′ and
30′ (p < 0.001). In group RP2, PVEPs were only recorded with the three biggest check sizes tested and
P100 amplitudes were significantly (p < 0.001) smaller than corresponding controls. The latency of the
P100 in RP patients increased (Figure 5b) and was significant in the RP2 group of patients at the check
sizes of 15′ and 30′ (p < 0.05).
4. Discussion
In this study, we described for the first time the P100 amplitude- and latency-check size functions
of RP patients, obtained from PVEPs recordings. Data show that RP produces a reduction of amplitude
and increment of latency of the P100 with all check sizes tested. The P100 amplitude-check size function
of the patients not only differs with controls in the overall reduction of amplitude, but also in the
check width at which the P100 reaches the maximum mean value. In both groups of RP patients,
the peak amplitude of P100 was obtained with the check width of 60′ instead the 15′ of controls.
Both functions reveal that the decrease in amplitude and increase in latency of the P100 in RP patients
occurs independently of the stimuli check size, at least in the range analyzed, and that the peak of the
P100 amplitude is obtained with a smaller spatial frequency (larger check size) than control normal
subjects. These results show that RP alters the activity of the visual cortex in a broader manner than
previously described [13,14,17].
PVEPs represent the response of visual cortex to appropriate stimulation of the ganglion cells in
the central retina [12,18]. It is thought that the differential effects of check size, revealed by the P100
amplitude- and latency-spatial functions, are due to the contributions of different populations of retinal
ganglion cells, according to their morphological and functional properties [19,20]. Thus, ganglion
cells most sensitive to small check size stimuli have a predominantly foveal location, smaller receptive
fields, and slower conduction velocity. On the other hand, the visual system is composed by two
main processing streams, the parvocellular and magnocellular pathways, with different functional
properties. The parvocellular system, that includes more than the 70% of the retinal ganglion cells,
is responsible for visual resolution and chromatic processing, whereas the magnocellular is responsible
for the detection of achromatic patterns of low spatial frequency and contrast [21,22]. The differences
showed by the P100 spatial functions, obtained with high and low contrasts stimuli (see Figure 4),
may reflect the differential participation of the two visual pathways. Thus, the lower P100 amplitude
obtained with contrasts of 16% and 6%, together with the absence of response to the smallest check
size used, indicates that P100 spatial functions obtained with low contrast are mainly due to the
implication of the magnocellular system. As shown in Figure 5, the P100 spatial functions in RP patients,
obtained with high contrast (100%) stimuli, were similar in several aspects to that obtained in control
subjects with low contrasts (16% and 6%) stimuli. Thus, in both cases, it was found an overall reduction
of P100 amplitude, peak amplitude with larger check size and non-recordable PVEPs with high spatial
frequency stimuli. These results suggest contrast detection alteration in these patients. In other words,
it is as if high contrast stimuli were perceived by RP patients as normal subjects perceive low contrast
stimuli. Visual handicaps in RP patients are not only due to the loss of photoreceptors. The retinal
dystrophy in RP, regardless of the initiating event or genetic defect, also implies profound functional
and morphological changes in the retina, including glial transformations, neuronal translocations,
neuronal loss, and the emergence of ectopic neurite complexes and creation of abnormal circuitries [23].
Thus, the alterations in the P100 amplitude- and latency-check size functions in RP must also be related
to the complex retinal remodeling that characterizes RP retinal degeneration and that affects both the
parvocellular and the magnocellular pathways [24]. The P100 is a relatively late component of PVEPs.
There is evidence that P100, generated by the activity of pyramidal cells in the primary visual cortex,
does not only depend on thalamic input, but also on top-down signals from the extrastriate visual
areas [25]. Furthermore, the amplitude and latency of PVEPs can also be modulated by the activation
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of visual attention neural networks [26]. Thus, the increase in latency of P100 in RP patients may be
due to deficits in synchronization and integration of subcortical and cortical inputs by the primary
visual cortex induced by the altered retinal outputs. Given that RP includes various types of retinal
dystrophies, it would be interesting to confirm these preliminary results in future studies with more
RP patients.
5. Conclusions
In summary, PVEPs spatial functions reveal that RP induces significant changes in the
electrophysiological activity of the visual cortex, particularly the neural processing of stimulus
contrast. The impact of the RP retinal degeneration in visual cortex functions must be considered in
the design of suitable vision rescue strategies in patients with RP.
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